熱門資訊> 正文

诺华的重症肌无力资产iptacopan获得FDA孤儿药地位

2025-12-20 03:57

諾華製藥(NVS) 0
Strategy (MSTR) 0

The US FDA has granted Orphan Drug designation to Novartis' (NVS) iptacopan for myasthenia gravis.
The drug, an oral, selective Factor B inhibitor, is already approved under the name Fabhalta for paroxysmal nocturnal hemoglobinuria and proteinuria.

More on Novartis

Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy - Slideshow
Novartis AG (NVS) Shareholder/Analyst Call Transcript
More pharmas expected to sign drug pricing deals with Trump on Friday - report
Novartis sees positive results when ianalumab added to Promacta for thrombocytopenia

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。